Vitalls
PrivateLast Round
Seed
Oct 26, 2026
Total Funding Raised
$2M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Vitalls operates in Healthcare & Life Sciences and is based in Dubai. Its latest recorded funding round was a Seed round in October 2026.
Vitalls is a healthtech company that provides a secure, AI-powered digital health passport platform for individuals to manage, store, and share their medical records.
Sector
Healthcare & Life Sciences
Verticals
Healthcare Analytics, Telemedicine, Medical AI, Patient Engagement, Vertical SaaS
Business Model
B2B2C
Customer Profile
Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vitalls Comparables
Compare Vitalls with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| eMed Support Systems | 78% | |
| Doctory | 77% | |
| Optimize Health | 76% |
For institutional investors. Book with your work email.
Vitalls Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 26, 2026
$2M round led by EST Growmore Pte Ltd
- Jul 23, 2026
Grew 60% QoQ, from 5 to 8 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 2, 2026
Vitalls receives a $1.5M Seed round commitment from EST Growmore as anchor investor in the United Arab Emirates on Oct 21st '26, with an option for a further $1 million to accelerate its AI-powered digital health passport.
- is_developingOct 22, 2026
Vitalls is developing an AI-powered platform that lets individuals and families store, manage, and share medical records across healthcare providers and international borders.
- is_developingOct 22, 2026
Vitalls, a United Arab Emirates healthtech startup, is developing an AI-powered digital health passport that lets individuals and families store, manage, and share medical records across healthcare providers and international borders, supported by $1.5M from EST Growmore and an option for an additional $1M.
- attends_eventOct 21, 2026
Vitalls attends the Abu Dhabi Future Health Summit in UAE on Oct 21st '26, where it announces an agreement for EST Growmore to invest US$1.5 million in its seed round.
- hiresOct 19, 2026
Vitalls appoints Dr. Dirk Richter, MD, PhD, as Board Advisor for Health Systems Strategy to support its international growth in United Arab Emirates on Oct 19th '26.
For institutional investors. Book with your work email.
Vitalls Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vitalls's valuation, stock price, and market status.
Is Vitalls a public or private company?
Vitalls is a private company.
What is the current stock price of Vitalls?
Vitalls is a private company, so its shares have no public market price. Caplight tracks Vitalls's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vitalls worth (valuation)?
Valuation information for Vitalls is not publicly available.
Can I buy Vitalls stock?
Vitalls shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vitalls's last funding round?
Vitalls's most recent funding round was Seed on October 26, 2026.
Who are the main investors in Vitalls?
Investor information for Vitalls is not publicly disclosed.
Will Vitalls IPO soon?
No public IPO plans have been announced for Vitalls.
How can I track Vitalls secondary market activity?
Caplight tracks bids, offers, and trades in Vitalls's shares on secondary markets.